Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.

Abstract excerpt

Although toxicogenomics originated as a field of primarily preclinical investigation, a variety of genomic approaches can also be employed during or after clinical development to identify biomarkers linked to drug exposure and/or drug safety. Comparing and contrasting the different pharmacogenomic approaches according to their scale (targeted, focused or exploratory) illustrates the potential utility of each type...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers
• Share to Biomedical Research
• Share to Drug Evaluation, Preclinical